EEG
ACHN

E.E. Geduld’s Achillion Pharmaceuticals ACHN Stock Holding History

E.E. Geduld’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-20,000
Closed -$151K – 292
2014
Q2 		$151K Buy
+20,000
New +$79.8K 0.09% 203

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

E.E. Geduld's ACHN Position: Q3 2014 in Review

E.E. Geduld sold out of Achillion Pharmaceuticals (ACHN) in Q3 2014, closing a stake of 20,000 shares — an estimated $151K sold.

E.E. Geduld first reported a position in ACHN in Q2 2014 and held it in 1 quarter. The position peaked at $151K in Q2 2014. 161 funds tracked by Wall St. Rank hold ACHN as of Q3 2014.

  • E.E. Geduld reported no remaining Achillion Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • E.E. Geduld sold 20,000 Achillion Pharmaceuticals shares in Q3 2014, an estimated $151K.
  • E.E. Geduld first reported a position in Achillion Pharmaceuticals in Q2 2014 and held it in 1 quarter.
  • E.E. Geduld's Achillion Pharmaceuticals position peaked at $151K in Q2 2014.
  • 161 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q3 2014.

Based on E.E. Geduld's 13F filing for Q3 2014, filed 30 Oct 2014.